A final decision on the proposal is expected by May 2019.
Immune checkpoint inhibitors and chimeric antigen receptor T cells can be highly effective against cancer, but can also harm the heart and...
SAN DIEGO – This is the first in-human study of a bispecific loop CAR in the United States.
SAN DIEGO – Ibrutinib treatment before and after CAR T-cell therapy in CLL patients may decrease the risk of severe cytokine release syndrome.
SAN DIEGO – A CAR T-cell construct engineered to enhance T-cell persistence and immune function induced high complete remission rates in a phase 1...
SAN DIEGO – Follow-up of patients who survived at least 1 year after CAR T-cell infusions suggests that the technology is safe.
From the Journals
Older patients with ccRCC may respond better than younger patients to phosphoinositide 3-kinase (PI3K) or checkpoint inhibition because of age-...
New studies highlight the role of CAR T-cell therapies in CLL, ALL, and DLBCL.